Conditions: Non-small Cell Lung Cancer
Interventions: Drug: adebrelimab + SHR-A2009; Drug: paclitaxel or pemetrexed combined with carboplatin +adebrelimab; Drug: adebrelimab + SHR-A2009; Drug: adebrelimab + SHR-A2009; Drug: adebrelimab; Drug: adebeliizumab + SHR-A2009; Drug: adebeliizumab + SHR-A2009; Drug: adebeliizumab + platinum-containing double chemotherapy; Drug: almonertinib combined with SHR-A2009; Drug: almonertinib combined with SHR-A2009; Drug: almonertinib; Drug: SHR-A2009 combined with almonertinib; Drug: almonertinib monotherapy
Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting Conditions: Non-small Cell Lung Cancer
Interventions: Drug: adebrelimab + SHR-A2009; Drug: paclitaxel or pemetrexed combined with carboplatin +adebrelimab; Drug: adebrelimab + SHR-A2009; Drug: adebrelimab + SHR-A2009; Drug: adebrelimab; Drug: adebeliizumab + SHR-A2009; Drug: adebeliizumab + SHR-A2009; Drug: adebeliizumab + platinum-containing double chemotherapy; Drug: almonertinib combined with SHR-A2009; Drug: almonertinib combined with SHR-A2009; Drug: almonertinib; Drug: SHR-A2009 combined with almonertinib; Drug: almonertinib monotherapy
Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting
